** Kura Oncology KURA.O shares jump 14% to $6.49 in pre-market trading
** KURA and Japan-based Kyowa Kirin 4151.T say the US FDA accepted marketing application for ziftomenib
** The drug, if approved, could be used to treat patients with acute myeloid leukemia, a type of blood cancer
** The disease affects about 22,000 people in the US every year, according to American Cancer Society
** Ziftomenib is a potential first-of-its-kind treatment for this aggressive form of leukemia, the cos say
** The FDA has granted priority review and is likely to decide by November 30 this year, they added
** YTD, stock down 34.7%, as of last close
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。